

ELECTRA THERAPEUTICS, INC.
Reported by
WESTLAKE BIOPARTNERS FUND I, L.P.

FORM 3
(Initial Statement of Beneficial Ownership)

Filed 09/21/26 for the Period Ending 09/21/26

Address	230 EAST GRAND AVENUE, SUITE S-100 SOUTH SAN FRANCISCO, CA, 94080
Telephone	(888) 743-2290
CIK	0002088082
Symbol	ETRA
Fiscal Year	12/31

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person * Westlake BioPartners Fund I, L.P.	2. Date of Event Requiring Statement (MM/DD/YYYY) 9/21/2026	3. Issuer Name and Ticker or Trading Symbol Electra Therapeutics, Inc. [ETRA]
(Last) (First) (Middle) C/O WESTLAKE BIOPARTNERS, LLC 3075 TOWNSGATE ROAD, SUITE 140	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☐ Director ☒ 10% Owner ☐ Officer (give title below) ☐ Other (specify below)	
(Street) WESTLAKE VILLAGE CALIFORNIA 91361	5. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ☐ Form filed by One Reporting Person ☒ Form filed by More than One Reporting Person
(City) (State) (Zip/Postal Code) UNITED STATES		
(Country)		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,527,136 ⁽³⁾	I	See footnote ⁽¹⁾
Common Stock	2,820,403 ⁽³⁾	I	See footnote ⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

- (1) Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (Seidenberg) is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
- (2) Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
- (3) Shares acquired upon the automatic conversion of redeemable preferred stock on a 1:1 basis upon the closing of the Issuer's initial public offering without the payment of further consideration. Each Reporting Person had previously waived its right to voluntarily convert such redeemable preferred stock.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Westlake BioPartners Fund I, L.P. C/O WESTLAKE BIOPARTNERS, LLC 3075 TOWNSGATE ROAD, SUITE 140 WESTLAKE VILLAGE CALIFORNIA 91361 UNITED STATES		X		
Westlake BioPartners GP I, LLC C/O WESTLAKE BIOPARTNERS, LLC 3075 TOWNSGATE ROAD, SUITE 140 WESTLAKE VILLAGE CALIFORNIA 91361 UNITED STATES		X		
Westlake BioPartners Fund II, L.P. C/O WESTLAKE BIOPARTNERS, LLC 3075 TOWNSGATE ROAD, SUITE 140 WESTLAKE VILLAGE CALIFORNIA 91361 UNITED STATES		X		
Westlake BioPartners GP II, LLC C/O WESTLAKE BIOPARTNERS, LLC 3075 TOWNSGATE ROAD, SUITE 140 WESTLAKE VILLAGE CALIFORNIA 91361 UNITED STATES		X		

Signatures

By: /s/ Jennifer L. Kercher, as Attorney-in-Fact

9/21/2026

—Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

* Form 3: SEC 1473 (03-26).